United States Radioimmunoassay Market Size, Share, and COVID-19 Impact Analysis, By Product (Analyzers, Reagents & Kits), By Application (Research and Clinical Diagnostics), and United States Radioimmunoassay Market Insights, Industry Trend, Forecasts to 2035

United States Radioimmunoassay Market Insights Forecasts to 2035

• The US Radioimmunoassay Market Size Was Estimated at USD 326.6 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 2.30% from 2025 to 2035
• The US Radioimmunoassay Market Size is Expected to Reach USD 419.4 Million by 2035

According to a research report published by Spherical Insights & Consulting, the United States Radioimmunoassay Market is anticipated to reach USD 419.4 million by 2035, growing at a CAGR of 2.30% from 2025 to 2035. The growing need for sensitive and precise diagnostic techniques in a variety of therapeutic settings propels the expansion of the market.

Market Overview

Radioimmunoassays (RIAs) are very sensitive and specific assays that employ radiolabeled molecules for quantifying amounts of antigen or antibody in a sample. The radioimmunoassay is a laboratory method and relies on the specificity of antigen-antibody interactions and the sensitive detection of radioisotopes to accurately quantify very small amounts of material, sometimes in the picogram range. RIAs are utilized relatively widely because of their sensitivity and ability to detect hormones at nanomolar and picomolar concentrations in biological fluids. RIA has become one of the main means of assessment within a clinical laboratory for diagnostic purposes, including measuring plasma concentrations of most of the hormones, screening for some drugs of abuse, for a hepatitis B surface antigen (HBsAg) screening of donated blood, and similar examples. RIAs have applications in the early detection of cancer, the treatment of peptic ulcer disease, research projects involving neurotransmitters, the detection of genera of infectious agents, allergen detection in food and dust, and many others. The U.S. dominates the RIA industry, pushed along by the growing awareness about chronic diseases such as cancer and thyroid disorders, where radioimmunoassay is often performed to monitor. With a well-educated and technologically capable workforce, plus the reliance on academic institutions for collaborative research, it is very easy to establish these methods of diagnostics and to continue to innovate in the delivery of healthcare. The U.S. continues to rise in this industry due to innovation brought about by value offered as well as clinical-level needs. For example, in february 2024, the Oak Ridge National Laboratory (ORNL) announced it was the first domestic supplier to commence the production of Iridium-192 (Ir-192), an important and widely used radioisotope in the industrial and medical fields, for the U.S. Department of Energy's Isotope Program. This will be the first Ir-192 produced domestically in nearly two decades, with the ultimate goal of lowering the U.S. reliance on foreign suppliers, no matter the industry or sector. The ability for diagnostic companies in the RIA sector to limit their reliance on foreign sources for isotopes allows them to scale sensitive assay technologies so that they can ensure a consistent production of test kits, as well as product R&D.

The US government's focus on precision medicine and personalized diagnostics, and a favorable regulatory environment will also stimulate the RIA market substantially.

Report Coverage

This research report categorizes the market for the United States radioimmunoassay market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the United States radioimmunoassay market. Recent market developments and competitive strategies such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the United States radioimmunoassay market.

Driving Factors

The growth of the United States radioimmunoassay market is fueled by the ability of RIA methods to detect trace levels of substances in relatively complex biological specimens, making it indispensable for applications even when traditional immunoassays fail to perform. The precision of RIA seeped into hormone analysis, drug monitoring, and surveillance of infectious agents in an early stage. Further, the reproducibility of the RIA methods through decades of laboratory practice has therefore cultivated confidence amongst clinicians and researchers to support continued relevance in the ever-competitive field of diagnostics.

Restraining Factors

The United States radioimmunoassay market faces obstacles like the high costs of specialized suites, radioactive waste disposal, and trained personnel create barriers to entry to the market. Additionally, the market has to contend with competing immunoassays such as ELISA and CLIA, which are equally accurate and do not use radioactive isotopes, and are also under the scrutiny of environmental and regulatory requirements for using radioactive materials.

Market Segmentation

The United States radioimmunoassay market share is classified into product and application.

• The reagents & kits segment held the largest market share in 2024 and is expected to grow at a remarkable CAGR during the forecast period.

The United States radioimmunoassay market is segmented by product into analyzers, reagents & kits. Among these, the reagents & kits segment held the largest market share in 2024 and is expected to grow at a remarkable CAGR during the forecast period. The segmental growth is driven based only on its frequent and essential use in disease diagnostic tests. The frequency of repeat orders combined with the importance of resemble reagent's role in the RIA process makes dominate the RIA market. Their high consumption and need for routine replacements by laboratories and hospitals support ongoing demand for reagents & kits. Numerous developments in kit formulations to improve specificity, lower background noise, etc. have strengthened the RIA market share.

• The clinical diagnostics segment held the highest revenue share in 2024 and is expected to grow at a significant CAGR during the forecast period.

Based on the application, the United States radioimmunoassay market is segmented into research and clinical diagnostics. Among these, the clinical diagnostics segment held the highest revenue share in 2024 and is expected to grow at a significant CAGR during the forecast period. The segmental growth is propelled by RIA identifies and precisely quantifies low concentrations of hormones, drugs and infectious agents well. An excellent example is its limitations for the diagnosis of thyroid disorders, abnormalities of adrenal function, and certain cancers. However, although RIA has been superseded in many routine laboratories by modern methodologies such as ELISA and chemiluminescent assays, it can be the preferential way to measure some analytes, given its greater degree of sensitivity and specificity when comparing a small number of analytes.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the United States radioimmunoassay market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Beckman Coulter, Inc.
• PerkinElmer, Inc.
• DRG International, Inc.
• MP Biomedicals, LLC
• Danaher
• Quidel
• GE HealthCare
• Becton Dickinson
• Abbott
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the United States, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the United States radioimmunoassay market based on the following segments:

United States Radioimmunoassay Market, By Product

• Analyzers
• Reagents & Kits

United States Radioimmunoassay Market, By Application

• Research
• Clinical Diagnostics